109
Registered trials
42
Recruiting
57
Completed trials
57
Sponsors
25
Countries
Phase III:
55
Phase II/III:
6
Phase II:
33
Phase I/II:
6
Phase III/IV:
1
Phase IV:
2
Phase I:
1
Phase I (Other):
2
Phase I (FiH):
3
Oversight events:
3 serious breaches
48 temporary halts
5 urgent safety measures
5 corrective measures
across 16 trials
View oversight register →
Indications tested
Non-small cell lung cancer
39
Non-small cell lung cancer metastatic
15
Non-small cell lung cancer stage IV
8
Non-small cell lung cancer stage III
3
Non-small cell lung cancer recurrent
3
Non-small cell lung cancer stage IIIB
3
Pleural mesothelioma malignant
1
Triple negative breast cancer
1
ALK gene rearrangement positive
1
Interstitial lung disease
1
Medullary thyroid cancer
1
Non-small cell lung cancer stage I
1
Sponsors using this IMP
AstraZeneca AB
14
F. Hoffmann-La Roche AG
7
Bristol-Myers Squibb Services Unlimited Company
6
Merck Sharp & Dohme LLC
6
Intergroupe Francophone De Cancerologie Thoracique
5
Regeneron Pharmaceuticals Inc.
5
AbbVie Deutschland GmbH & Co. KG
4
Bristol Myers Squibb International Corporation
3
Daiichi Sankyo Inc.
3
Fondazione Ricerca Traslazionale
3
Revolution Medicines Inc.
3
Boehringer Ingelheim Espana S.A.
2
All trials — page 2
109 total-
HARMONi-3 Recruiting
Showing 25–48 of 109 trials